SG11202108099WA - LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFβ AND USES THEREOF - Google Patents

LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFβ AND USES THEREOF

Info

Publication number: SG11202108099WA
Authority: SG; Singapore
Prior art keywords: tgfβ; specific inhibitors; ltbp complex; ltbp; complex
Prior art date: 2019-01-30

Application number

SG11202108099WA

Inventor

Thomas Schurpf

Justin W Jackson

George Coricor

Abhishek Datta

Stefan Wawersik

Christopher Littlefield

Adam Fogel

Frederick Streich

Caitlin Stein

Julia Mccreary

Matthew Salotto

Original Assignee

Scholar Rock Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2019-01-30

Filing date

2020-01-30

Publication date

2021-08-30

2020-01-30 Application filed by Scholar Rock Inc filed Critical Scholar Rock Inc

2021-08-30 Publication of SG11202108099WA publication Critical patent/SG11202108099WA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Urology & Nephrology (AREA)
Gastroenterology & Hepatology (AREA)
Pulmonology (AREA)
Heart & Thoracic Surgery (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Cardiology (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

SG11202108099WA 2019-01-30 2020-01-30 LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFβ AND USES THEREOF SG11202108099WA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201962798927P	2019-01-30	2019-01-30
PCT/US2020/015915 WO2020160291A2 (en)	2019-01-30	2020-01-30	LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFβ AND USES THEREOF

Publications (1)

Publication Number	Publication Date
SG11202108099WA true SG11202108099WA (en)	2021-08-30

Family

ID=69423073

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11202108099WA SG11202108099WA (en)	2019-01-30	2020-01-30	LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFβ AND USES THEREOF

Country Status (21)

Country	Link
US (3)	US11214614B2 (en)
EP (1)	EP3689905A3 (en)
JP (1)	JP2022524281A (en)
KR (1)	KR20210121174A (en)
CN (1)	CN113677711A (en)
AR (1)	AR117918A1 (en)
AU (1)	AU2020216177A1 (en)
BR (1)	BR112021015056A2 (en)
CA (1)	CA3128042A1 (en)
CL (1)	CL2021001993A1 (en)
CO (1)	CO2021010062A2 (en)
CR (1)	CR20210416A (en)
DO (1)	DOP2021000161A (en)
EA (1)	EA202192130A1 (en)
IL (1)	IL285076A (en)
MA (1)	MA54845A (en)
MX (1)	MX2021009175A (en)
PE (1)	PE20220279A1 (en)
SG (1)	SG11202108099WA (en)
TW (1)	TW202043267A (en)
WO (1)	WO2020160291A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR117918A1 (en)	2019-01-30	2021-09-01	Scholar Rock Inc	COMPLEX-SPECIFIC LTBP INHIBITORS OF TGFb AND THEIR USES
PE20221447A1 (en)	2019-08-28	2022-09-21	Chugai Pharmaceutical Co Ltd	LATENT ANTI-TGF-BETA 1 ANTIBODIES AND METHODS OF USE
CA3167427A1 (en) *	2020-01-11	2021-07-15	Scholar Rock, Inc.	Tgfb inhibitors and use thereof
WO2022204581A2 (en)	2021-03-26	2022-09-29	Scholar Rock, Inc.	Tgf-beta inhibitors and use thereof
EP4348260A2 (en)	2021-06-03	2024-04-10	Scholar Rock, Inc.	Tgf-beta inhibitors and therapeutic use thereof
IL309078A (en) *	2021-06-23	2024-02-01	Scholar Rock Inc	A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders
US20240301073A1 (en)	2021-07-14	2024-09-12	Scholar Rock, Inc.	LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFb1 AND USES THEREOF
WO2024187051A1 (en)	2023-03-07	2024-09-12	Scholar Rock, Inc.	Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US4485045A (en)	1981-07-06	1984-11-27	Research Corporation	Synthetic phosphatidyl cholines useful in forming liposomes
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4544545A (en)	1983-06-20	1985-10-01	Trustees University Of Massachusetts	Liposomes containing modified cholesterol for organ targeting
JPS6147500A (en)	1984-08-15	1986-03-07	Res Dev Corp Of Japan	Chimera monoclonal antibody and its preparation
EP0173494A3 (en)	1984-08-27	1987-11-25	The Board Of Trustees Of The Leland Stanford Junior University	Chimeric receptors by dna splicing and expression
GB8422238D0 (en)	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
CA1340288C (en)	1988-09-02	1998-12-29	Robert Charles Ladner	Generation and selection of novel binding proteins
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
US6291158B1 (en)	1989-05-16	2001-09-18	Scripps Research Institute	Method for tapping the immunological repertoire
US5013556A (en)	1989-10-20	1991-05-07	Liposome Technology, Inc.	Liposomes with enhanced circulation time
US5427908A (en)	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
DK0585287T3 (en)	1990-07-10	2000-04-17	Cambridge Antibody Tech	Process for producing specific binding pair elements
US6172197B1 (en)	1991-07-10	2001-01-09	Medical Research Council	Methods for producing members of specific binding pairs
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
WO1992009690A2 (en)	1990-12-03	1992-06-11	Genentech, Inc.	Enrichment method for variant proteins with altered binding properties
EP1820858B1 (en)	1991-03-01	2009-08-12	Dyax Corporation	Chimeric protein comprising micro-protein having two or more disulfide bonds and embodiments thereof
AU662148B2 (en)	1991-04-10	1995-08-24	Scripps Research Institute, The	Heterodimeric receptor libraries using phagemids
DE4122599C2 (en)	1991-07-08	1993-11-11	Deutsches Krebsforsch	Phagemid for screening antibodies
ES2227512T3 (en)	1991-12-02	2005-04-01	Medical Research Council	PRODUCTION OF ANTIBODIES AGAINST SELF-ANTIGENS FROM REPERTORIES OF ANTIBODY SEGMENTS FIXED IN A PHOTO.
US5786464C1 (en)	1994-09-19	2012-04-24	Gen Hospital Corp	Overexpression of mammalian and viral proteins
US6114148C1 (en)	1996-09-20	2012-05-01	Gen Hospital Corp	High level expression of proteins
GB9722131D0 (en)	1997-10-20	1997-12-17	Medical Res Council	Method
US6492497B1 (en)	1999-04-30	2002-12-10	Cambridge Antibody Technology Limited	Specific binding members for TGFbeta1
US7138496B2 (en)	2002-02-08	2006-11-21	Genetastix Corporation	Human monoclonal antibodies against human CXCR4
EP1674480A4 (en)	2003-09-04	2007-06-20	Riken	Antibody recognizing tgf-beta activation controlling region section
WO2006086469A2 (en)	2005-02-08	2006-08-17	Genzyme Corporation	Antibodies to tgfbeta
PL1874818T3 (en)	2005-04-22	2011-09-30	Lilly Co Eli	Tgf beta 1 specific antibodies
US8877688B2 (en)	2007-09-14	2014-11-04	Adimab, Llc	Rationally designed, synthetic antibody libraries and uses therefor
US20110165063A1 (en) *	2009-01-29	2011-07-07	Abbott Laboratories	Il-1 binding proteins
WO2011102483A1 (en) *	2010-02-19	2011-08-25	独立行政法人理化学研究所	HUMAN LAP TGF-β BINDING ANTIBODY
CN116333113A (en) *	2011-06-03	2023-06-27	佐马技术有限公司	Antibodies specific for TGF-beta
EP2916867A4 (en)	2012-11-06	2016-10-05	Scholar Rock Inc	Compositions and methods for modulating cell signaling
SG11201508681QA (en) *	2013-05-06	2015-11-27	Scholar Rock Inc	Compositions and methods for growth factor modulation
AU2015365168B2 (en)	2014-12-19	2021-08-05	Chugai Seiyaku Kabushiki Kaisha	Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of use
US10167334B2 (en)	2015-04-03	2019-01-01	Xoma Technology Ltd.	Treatment of cancer using anti-TGF-BETA and PD-1 antibodies
BR112018004981A2 (en) *	2015-09-15	2018-10-09	Scholar Rock, Inc.	anti-pro-myostatin / latent myostatin antibodies and uses thereof.
CN109071646A (en)	2016-03-11	2018-12-21	供石公司	TGF β 1- binding domain-immunoglobulin and application thereof
PE20190205A1 (en)	2016-06-13	2019-02-07	Scholar Rock Inc	USE OF MYOSTATIN INHIBITORS AND COMBINATION THERAPIES
KR102577551B1 (en)	2016-07-14	2023-09-11	스칼러 락, 인크.	TGFβ antibodies, methods and uses
US10375984B2 (en)	2016-07-18	2019-08-13	R.J. Reynolds Tobacco Company	Nonwoven composite smokeless tobacco product
CA3031168A1 (en)	2016-08-12	2018-02-15	Merck Patent Gmbh	Combination therapy for cancer
TW201811827A (en) *	2016-09-05	2018-04-01	日商中外製藥股份有限公司	Anti-TGF-beta 1 antibodies and methods of use
PE20191661A1 (en) *	2017-01-06	2019-11-11	Scholar Rock Inc	INHIBITORS OF TGF BETA1 ISOFORM-SPECIFIC CONTEXT-PERMISIVES AND USE OF THE SAME
JP2020514290A (en)	2017-01-07	2020-05-21	メルクパテントゲーエムベーハー	Dosing Schedule and Dosage Form for Targeted TGF-B Inhibition
EA201991729A1 (en)	2017-01-20	2019-12-30	Санофи	ANTIBODIES TO TGF-BETA AND THEIR APPLICATION
CN110573532B (en)	2017-03-02	2024-04-16	加拿大国家研究委员会	TGF-beta receptor ectodomain fusion molecules and uses thereof
MA49690A (en) *	2017-07-28	2021-05-19	Scholar Rock Inc	SPECIFIC INHIBITORS OF THE TGF-BETA 1 LTBP COMPLEX AND THEIR USES
TW202005981A (en)	2018-07-11	2020-02-01	美商供石公司	HIGH-AFFINITY, ISOFORM-SELECTIVE TGFβ1 INHIBITORS AND USE THEREOF
TW202019957A (en)	2018-07-11	2020-06-01	美商供石公司	Tgfβ1 inhibitors and use thereof
AR117918A1 (en)	2019-01-30	2021-09-01	Scholar Rock Inc	COMPLEX-SPECIFIC LTBP INHIBITORS OF TGFb AND THEIR USES

2020
- 2020-01-30 AR ARP200100240A patent/AR117918A1/en unknown
- 2020-01-30 MA MA054845A patent/MA54845A/en unknown
- 2020-01-30 KR KR1020217027487A patent/KR20210121174A/en active Search and Examination
- 2020-01-30 SG SG11202108099WA patent/SG11202108099WA/en unknown
- 2020-01-30 CN CN202080026577.3A patent/CN113677711A/en active Pending
- 2020-01-30 JP JP2021543179A patent/JP2022524281A/en active Pending
- 2020-01-30 BR BR112021015056A patent/BR112021015056A2/en unknown
- 2020-01-30 CR CR20210416A patent/CR20210416A/en unknown
- 2020-01-30 WO PCT/US2020/015915 patent/WO2020160291A2/en active Application Filing
- 2020-01-30 AU AU2020216177A patent/AU2020216177A1/en active Pending
- 2020-01-30 CA CA3128042A patent/CA3128042A1/en active Pending
- 2020-01-30 EA EA202192130A patent/EA202192130A1/en unknown
- 2020-01-30 TW TW109102916A patent/TW202043267A/en unknown
- 2020-01-30 MX MX2021009175A patent/MX2021009175A/en unknown
- 2020-01-30 EP EP20154732.0A patent/EP3689905A3/en active Pending
- 2020-01-30 PE PE2021001254A patent/PE20220279A1/en unknown
- 2020-08-19 US US16/997,438 patent/US11214614B2/en active Active
2021
- 2021-07-22 IL IL285076A patent/IL285076A/en unknown
- 2021-07-29 CO CONC2021/0010062A patent/CO2021010062A2/en unknown
- 2021-07-29 CL CL2021001993A patent/CL2021001993A1/en unknown
- 2021-07-30 DO DO2021000161A patent/DOP2021000161A/en unknown
- 2021-11-19 US US17/530,786 patent/US11365245B2/en active Active
2022
- 2022-05-17 US US17/746,325 patent/US20220363741A1/en active Pending

Also Published As

Publication number	Publication date
KR20210121174A (en)	2021-10-07
DOP2021000161A (en)	2021-09-15
CN113677711A (en)	2021-11-19
MX2021009175A (en)	2021-09-14
US20210047396A1 (en)	2021-02-18
MA54845A (en)	2021-09-29
IL285076A (en)	2021-09-30
EA202192130A1 (en)	2021-12-28
JP2022524281A (en)	2022-05-02
EP3689905A2 (en)	2020-08-05
EP3689905A3 (en)	2021-02-24
CA3128042A1 (en)	2020-08-06
US20220064276A1 (en)	2022-03-03
PE20220279A1 (en)	2022-02-25
CL2021001993A1 (en)	2022-04-08
US11365245B2 (en)	2022-06-21
AR117918A1 (en)	2021-09-01
CO2021010062A2 (en)	2021-08-09
BR112021015056A2 (en)	2022-01-11
CR20210416A (en)	2021-09-14
AU2020216177A1 (en)	2021-09-23
TW202043267A (en)	2020-12-01
WO2020160291A3 (en)	2020-09-10
US20220363741A1 (en)	2022-11-17
WO2020160291A9 (en)	2020-10-15
US11214614B2 (en)	2022-01-04
WO2020160291A2 (en)	2020-08-06

Publication	Publication Date	Title
IL285076A (en)	2021-09-30	Ltbp complex-specific inhibitors of tgfβ and uses thereof
IL288381A (en)	2022-01-01	Tead inhibitors and uses thereof
IL288384A (en)	2022-01-01	Tead inhibitors and uses thereof
IL287940A (en)	2022-01-01	Fgfr inhibitors and methods of use thereof
IL283592A (en)	2021-07-29	Inhibitors of apol1 and methods of using same
IL284508A (en)	2021-08-31	Irreversible inhibitors of menin-mll interaction
IL287751A (en)	2022-01-01	Kcnt1 inhibitors and methods of use
IL281939A (en)	2021-05-31	Inhibitors of vap-1
IL287768A (en)	2022-01-01	Kcnt1 inhibitors and methods of use
IL287973A (en)	2022-01-01	Acss2 inhibitors and methods of use thereof
IL276711A (en)	2020-09-30	Arginase inhibitors and methods of use thereof
IL288747A (en)	2022-02-01	Inhibitors of integrated stress response pathway
IL285697A (en)	2021-10-31	Inhibitors of integrated stress response pathway
IL289914A (en)	2022-03-01	Enzyme inhibitors
IL279151A (en)	2021-01-31	Inhibitors of integrated stress response pathway
IL289863A (en)	2022-03-01	Enzyme inhibitors
IL281815A (en)	2021-05-31	Inhibitors of vap-1
IL280924A (en)	2021-04-29	Arginase inhibitors and methods of use thereof
IL289778A (en)	2022-03-01	Enzyme inhibitors
SG11202110272SA (en)	2021-10-28	Prmt5 inhibitors and uses thereof
IL286485A (en)	2021-12-01	Pi4-kinase inhibitors and methods of using the same
IL289783A (en)	2022-03-01	Enzyme inhibitors
EP4161917A4 (en)	2024-08-28	Grk2 inhibitors and uses thereof
EP3744722A4 (en)	2021-11-03	ß-LACTAMASE INHIBITOR AND USE THEREOF
IL289127A (en)	2022-02-01	Ppm1a inhibitors and methods of using same